Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 30, 2014
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Accelerating Spirocyclic Polyketide Synthesis
Powerful flow chemistry techniques used for complex multi-stage synthesis of spirocyclic polyketides.
MS Drug Candidate Shows Promise for Ulcerative Colitis
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.
First Atlas of Body Clock Gene Expression in Mammals Informs Timing of Drug Delivery
Penn Medicine study has implications for 100 top-selling US drugs, half of which target daily-oscillating genes.
New Technique has Profound Implications for Drug Development
The method, developed by Scripps Research Institute chemists, expands options for making pure batches of ‘one-handed’ molecules.
Blood Test Developed to Diagnose Early Onset Alzheimer’s Disease
New blood-test could predict a person’s risk of developing AD much earlier than is currently possible.
Tea and Citrus Products Could Lower Ovarian Cancer Risk
New UEA research finds that women who consume foods containing flavonols and flavanones significantly decrease their risk of developing epithelial ovarian cancer.
TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease.
Heart Drug May Help Treat ALS, Mouse Study Shows
Scientists blocked the enzyme in ALS astrocytes using digoxin, a medication used in the treatment of heart failure.
Team Discovers How Microbes Build a Powerful Antibiotic
Researchers discovery opens up new avenues of research into thousands of similar molecules.
LLNL, UC Davis Partner to Personalize Cancer Medications
With a $7.8 million, five-year grant from the NIH researchers are utilizing accelerator mass spectrometry for cancer research.
Scroll Up
Scroll Down
Return
The use of 3D human liver microtissues for evaluating repeat dose toxicity
Dr. Simon Messner, Product Manager Toxicology, InSphero AG
Date Posted: Monday, January 13, 2014
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



InSphero Wins ACES Award as Top European Academic Enterprise in Life Sciences
Second honor in three weeks continues momentum for leading supplier of 3D microtissues for in vitro toxicity and efficacy testing.
Wednesday, October 15, 2014
InSphero Named #1 Swiss Startup for 2014
Leading supplier of 3D microtissues for in vitro toxicity and efficacy testing earns top honors in annual Swiss startup competition.
Saturday, October 04, 2014
InSphero Publishes 3D Tumor-Stroma Model for Non-Small Cell Lung Cancer
PLOS One article delivers promising co-culture method to mimic tumor microenvironment, demonstrating potential for biomarker and drug discovery.
Thursday, April 24, 2014
InSphero Announces Collaboration with NCATS
Study to characterize 460 NCATS anti-cancer agents in 3D tumor models generated using InSphero technology.
Friday, March 21, 2014
InSphero Hires New Director of Global Marketing
Randy Strube, Ph.D. joins company to strengthen InSphero's marketing team.
Thursday, January 30, 2014
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv